. 
The first patient was given a dose of the Coronavirus T-cell vaccine from Norwegian company Nykode Therapeutics in a clinical trial.
In total, the company selected three candidates for vaccines against the coronavirus. These candidates will receive T-cell and RBD vaccines and they are currently undergoing clinical trials, writes Dagens Medisin.
Research is conducted at Oslo University Hospital and Haukeland University Hospital. The goal of developing a T-cell vaccine is to provide a broader immune response against the coronavirus, which also works against new variants.
In addition, it should be easier to produce than the pfizer and Moderna mRNA vaccines because they use plasmid DNA, which is usually an intermediate step in the production of mRNA vaccines.
Nykode Therapeutics strongly believes in its vaccine, which is still far from being approved and widely used. Michael Engsig, CEO, says preclinical studies have shown that the vaccine is well tolerated and provides good cross-protection.
“What we're trying to achieve with this T-cell vaccine is to provide longer-term protection. Better cross-protection against new variants and a wider therapeutic window when it comes to vaccination. It is also a vaccine candidate that is easier to manufacture, distribute and administer. This is essential to deliver vaccines to parts of the world where mRNA vaccines present a challenge, says Dagens Medisin.
NTB Source
Also read our next article: New vaccine ...
